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Dynamics during Escherichia coli
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Single Drugs and Drug Pairs
Rachel A. Hickman, Christian Munck and Morten O. A. Sommer*
Bacterial Synthetic Biology, Novo Nordisk Foundation, Center for Biosustainability, Technical University of Denmark, Kongens
Lyngby, Denmark
Understanding the evolutionary processes that lead to antibiotic resistance can help
to achieve better treatment strategies. Yet, little is known about the dynamics of
the resistance alleles during adaptation. Here, we use population sequencing to
monitor genetic changes in putative resistance loci at several time-points during
adaptive evolution experiments involving five different antibiotic conditions. We monitor
the mutational spectra in lineages evolved to be resistant to single antibiotics
[amikacin (AMK), chloramphenicol (CHL), and ciprofloxacin (CIP)], as well as antibiotic
combinations (AMK + CHL and CHL + CIP). We find that lineages evolved to antibiotic
combinations exhibit different resistance allele dynamics compared with those of single-
drug evolved lineages, especially for a drug pair with reciprocal collateral sensitivity.
During adaptation, we observed interfering, superimposing and fixation allele dynamics.
To further understand the selective forces driving specific allele dynamics, a subset of
mutations were introduced into the ancestral wild type enabling differentiation between
clonal interference and negative epistasis.
Keywords: antibiotics, allelic dynamics, population frequency sequencing
INTRODUCTION
Bacteria have an impressive ability to adapt to changes in their environment. Their large population
sizes and short generation times allow bacteria to rapidly evolve and adapt in response to
environmental perturbations. This either occurs via the horizontal acquisition of new genes or
through mutations of existing genes. In the latter case, random single nucleotide variants (SNVs)
or insertions/deletions (INDELs) in the genome drive the evolution of new traits.
The ability of a mutated allele to establish itself within a population depends on complex
interplay between the positive selection for the conferred benefit of the mutation, random genomic
drift, and negative selection against any associated fitness costs of the mutation. Consequently,
novel mutant alleles often arise within a bacterial population but whilst they are at a low frequency
they can easily be lost due to genomic drift (Gerrish and Lenski, 1998). If a novel mutant allele
provides an advantageous phenotype, then it can become established within the population (Fogle
et al., 2008). Once a mutant allele becomes established within a bacterial population, it can become
fixed or compete with other subsequent mutant alleles that are present within the population;
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this process is known as clonal interference (Gerrish and
Lenski, 1998; Fogle et al., 2008). The population size is often
the governing factor that determines whether a mutant allele
becomes fixed or lost within a bacterial population. In a
small bacterial population, the establishment of mutations is
a rare event; thus, the mutant allele has a greater likelihood
of becoming fixed. By contrast, the opposite is true in large
bacterial populations in which competition between mutations is
more likely to occur, thus reducing the likelihood of a mutation
becoming fixed within a population (Wilke, 2004; Good et al.,
2012).
By identifying SNVs and INDELs at the population level
at different time points during adaptation to a physical or a
chemical perturbation, it is possible to uncover the trajectories
through which a population evolves. Studies of such evolutionary
trajectories have identified the population genetic dynamics
underlying adaptation to different diverse perturbations, such as
glucose being a limiting nutrient (Barrick et al., 2009; LaCroix
et al., 2015) and antibiotic exposure (Toprak et al., 2011; Zhang
et al., 2015; Feng et al., 2016).
An interesting phenomenon that often accompanies
mutational responses to an environmental perturbation
is the emergence of collateral effects. This phenomenon
describes situations in which the adaptive mutations acquired in
response to one perturbation affect the cell’s tolerance of other
perturbations. Such collateral effects have been found in bacteria
(Szybalski and Bryson, 1952; Imamovic and Sommer, 2013; Lázár
et al., 2013; Munck et al., 2014; Oz et al., 2014; Pál et al., 2015),
viruses (Miedema et al., 2013), and human cell lines (Cerezo
et al., 2015; Zhao et al., 2016).
Fundamentally, collateral effects can be divided into two
categories: collateral resistance and collateral sensitivity.
Collateral resistance involves situations in which increased
tolerance to one xenobiotic perturbation also provides increased
tolerance to other xenobiotic perturbations. By contrast,
collateral sensitivity describes situations in which increased
tolerance to one perturbation is accompanied by increased
sensitivity to other perturbations. In a recent study, we
investigated how bacterial populations respond to a dual
selection pressure relative to a single selection pressure (Munck
et al., 2014). Over the course of 14 days, bacterial populations
adaptively evolved to either single antibiotics or combinations
of two antibiotics. Interestingly, we found that the presence
of collateral sensitivity between two drugs significantly limited
the population’s capacity to evolve resistance. In the current
study, we follow the evolutionary events at key genetic loci
in bacterial populations that have been exposed to increasing
concentrations of either a single antibiotic or combinations of
two antibiotics (Munck et al., 2014). We investigated lineages
that evolved resistance to amikacin (AMK), chloramphenicol
(CHL), ciprofloxacin (CIP), amikacin + chloramphenicol
(AMK–CHL) and chloramphenicol+ ciprofloxacin (CHL–CIP).
The AMK–CHL drug combination was selected because it was
found to generate evolutionary tension that suppressed the
evolution of antimicrobial resistance, whereas the CHL–CIP
combination was chosen because the component drugs have
complementary evolutionary trajectories that enhance resistance
evolution toward the combination. In this study, amplicon
population sequencing and genome engineering were used to
characterize the evolutionary dynamics of the responses to the
individual antibiotics and antibiotic combinations.
MATERIALS AND METHODS
Bacterial Strains
For the adaptation evolution experiment and the generation of
samples for collection in this study, the bacterial strain used
was MG1655, which is an E. coli K-12 MG1655 wild type
(Blattner et al., 1997). Further characterization experiments were
performed on successfully recombined strains to reintroduce
given mutations (Table 1).
Sample Revival and DNA Extraction
Microtiter plates saved from Munck et al. (2014) were defrosted
for 30 min at 4◦C. To prevent aerosol contamination, the plates
were centrifuged at 300 × g for 5 s before seal removal. To
revive our samples, 150 µL were transferred to new tubes with
500 µL LB media and incubated at 37◦C for 3 h. Genomic DNA
was extracted using Genomic Mini Kits in accordance with the
manufacturer’s protocol (A&A Biotechnologies, Gdynia, Poland).
Resistance Allele Primer Design
The loci that were selected for sequencing were chosen based
on knowledge of their involvement in antibiotic resistance and
their mutation profiles in the end-point sequenced original
evolved lineages, and the population level loci sequencing
was performed on days 2, 4, 6, 8, 10 and 12 (Figure 1A).
For this study, we monitored the following mutations of
AMK: cpxA, fusA, and sbmA; for CHL, we monitored the
following mutations: acrR, marR, rob, and soxR; for CIP, we
monitored the following mutations: acrR, gyrA, and soxR; for
AMK + CHL, we monitored the following mutations: acrR,
cpxA, fusA, marR, rob, and soxR; and for CHL + CIP, we
monitored the following mutations: acrR, gyrA, marR, rob,
and soxR. We believe that these loci cover important genomic
locations that could begin to unravel important interactions
in intrinsic antibiotic resistance. The primers were designed
with overhangs to allow for barcoding with Nextera XT indices
in accordance with the Illumina 16S Metagenomic Sequencing
Protocol (Illumina Protocol Online) to amplify 12 different
genomic regions (Supplementary Table S1) in areas with known
resistance-causing SNPs. All primers were tested on E. coli-K12
wild-type genomic DNA, and the PCR products were verified by
1% agarose gel electrophoresis with GelRed (Biotium, Freemont,
CA, United States).
Amplicon Library Preparation and
Sequencing
All samples were amplified using the primers listed in
Supplementary Table S1 according to the descriptions in the
above section for each drug condition. Each PCR reaction was
performed in 0.2-mL sterile PCR tubes that contained 10-µL
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TABLE 1 | Recombineered bacterial strains.
Bacterial strain Observed bacterial
population variant
Amino acid change Genomic change
MG1655: marR C328T CHL Lineage C marR Gln110∗ marR C328T
MG1655: marR T251A CHL–CIP Lineage A marR Val84Glu marR T251A
MG1655: gyrA 247_249delTCG CHL–CIP Lineage A gyrA Ser83del gyrA 247_249delTCG
MG1655: rob G467A CHL Lineage C rob Arg156His rob G467A
MG1655: gyrA247_249delTCG + marR T251A CHL–CIP Lineage A gyrA Ser83del + marR Val84Glu gyrA 247_249delTCG + marR
T251A
MG1655: marR C328T + rob G467A marR Gln110∗ + rob Arg156His marR C328T + rob G467A
MG1655 Ancestral wild type
∗Non-sense mutation.
Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher
Scientific, United States), 0.5 µM forward primer, 0.5 µM
reverse primer, 1 µL DNA template and H20 to a total reaction
volume of 20 µL. The PCR amplification consisted of an initial
denaturation at 98◦C for 30 s, 30 cycles consisting of 98◦C for 10 s
denaturation, 65◦C for 10 s annealing, 72◦C for 15 s elongation,
72◦C for 60 s for final extension, and subsequent holding
at 4◦C. To validate correct amplification, gel electrophoresis
FIGURE 1 | Experimental overview of the investigation from sample collection description, adaptation laboratory evolution (ALE) and amplicon
frequency workflow. (A) Background for our frozen sample conditions showing five drug conditions (AMK, CHL, CIP, AMK–CHL, and CHL–CIP) each with three
lineages (Lineages A, B, C) covering six time points (days 2, 4, 6, 8, 10, and 12) for the laboratory adaptation experiments. (B) The workflow used to assess different
loci from different drug conditions, lineages, and time points in which (1) the DNA was extracted from the different samples, (2) each sample has amplicons for each
locus generated by primers that had a DNA amplifying region and an Illumina Nextera XT compatible overhang, (3) these were then barcoded using indices from the
Illumina Nextera XT library preparation kit, (4) all of the generated amplicons were pooled together based on fragment size and concentration, (5) the pooled
amplicon library was sequenced on the MiSeq Illumina sequencing platform, (6) each sample was sorted by barcode, and each was used to generate a file to map
to the reference genome and call variants in the bacterial population and to calculate their frequencies.
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was performed with 1% agarose gel stained with ethidium
bromide. After verification, all the different locus amplicons that
belonged to the same drug condition, lineage and time point
were pooled together. The PCR products were cleaned with
an Agencourt AMPure XP PCR purification system according
to the manufacturer’s online protocol (Beckman Coulter 2013).
The barcoding of the amplicons was achieved via a second
PCR amplification that was performed in 0.2-mL sterile PCR
tubes that contained 25 µL Phusion Flash High-Fidelity PCR
Master Mix (Thermo Fisher Scientific), 5 µL Nextera XT
index 1 (N7XX; Illumina), 5 µM Nextera XT index 2 (S5XX;
Illumina), 5 µL of the pooled amplicons and H20 to a total
reaction volume of 50 µL. The PCR amplification used an
initial denaturation of 98◦C for 30 s, 8 cycles consisting of
98◦C for 10 s denaturation, 65◦C for 10 s annealing, 72◦C
for 15 s elongation, 72◦C for 60 s for final extension and
subsequent holding at 4◦C. The barcoded amplicons were cleaned
according to the instructions of Agencourt AMPure XP PCR
purification systems (Beckman Coulter 2013). The barcoded
amplicons were measured for their DNA concentrations with
Qubit dsDNA HS Assay kits on a Qubit Fluorometer (Thermo
Fisher Scientific Inc. 2015) and average fragment size with Agilent
DNA 1000 kits on an Agilent 2100 bioanalyzer instrument
(Agilent Technologies 2013). Next, the barcoded amplicons
were pooled based on fragment size and DNA concentration
value to form a sequencing library. The sequencing library was
sequenced on the MiSeq sequencing platform (Illumina, United
States).
Sequence Analysis
All raw sequencing reads from our amplicon sequencing have
been deposited in the Sequence Read Archive (SRA) under
the BioProject accession number PRJNA328094. The sequencing
reads were mapped to the reference genome (GenBank accession
NC_000913) using the CLC genomics workbench (Qiagen).
These files were exported and used for coverage analysis. The
CLC genomic workbench (Qiagen) and the statistical program
R (R Core Team, 2014) were used to verify the sequencing
coverage mapping read files. Coverage plots were generated,
and any amplicons that were below our set threshold of 1000
read coverage were re-done until our threshold was achieved to
ensure good quality data (Supplementary Figures S1–S5). To
detect variants, all mappings were analyzed with the basic variant
detection calling function of the CLC Genomic Workbench
(Qiagen). The files were further analyzed using the program
R (R Core Team, 2014). Our detected variants are listed in
Supplementary Table S2.
Recombineering for Direct Mutagenesis
For the single mutant variants, the ancestral wild-type E. coliK-12
MG1655 was transformed with the transient mutator plasmid
PMA7sacB (GenBank accession KT285941) (Lennen et al.,
2016). For each single variant mutation, two recombineering
cycling rounds were performed with E. coli K-12 MG1655
harboring the PMA7sacB plasmid according to the MAGE
cycling with the single-stranded oligonucleotides (ss-oligos)
with verification primers (Supplementary Table S3) and
plasmid curing described by Lennen et al. (2016). Direct
mutagenesis verification was confirmed by Sanger sequencing
performed with Eurofins Mix2Seq kits according to the
manufacturer’s instructions (Eurofins Genomics, Esbersberg,
Germany). After verification, the double-mutant variants
were created by taking one of the single-mutant variants
from the observed double-mutant pair and transforming
it with the PMA7sacB plasmid. Recombineering with
the other mutant variant ss-oligo was performed in two
rounds as previously described. Plasmid curing was also
performed.
Characterization of the Recombineered
Mutation Variant Strains
The relative growth rate was used as an indicator of fitness and
was assessed for all the recombineered strains and wild type.
To measure relative growth fitness, overnight cultures in LB
medium were diluted to 1 × 106 CFU/mL and then added to
96-well microtiter plates with a medium negative control. All
procedures were performed in eight biological replicates with two
technical replicates to allow for the calculation of the relative
growth rate. The growth of the samples was done at 37◦C with
shaking for 10 s and kinetic measurements on ELx808 absorbance
microplate reader with Gen5 software (BioTek Instruments Inc.,
Winooski, VT, United States). Optical density measurements
were taken at 630 nm (OD630) every 10 min. Exponential
growth was defined by OD630 values between 0.02 and 0.1.
To calculate relative growth, R statistical software was used
to find the doubling time (Td) of each of the strains and
the standard deviation (Td SD) and then to calculate relative
growth rate, and the recombineered strain Td value was divided
by the wild-type Td value. Selective advantage was measured
by performing IC90 determination assays with the antibiotic
drug condition in which the mutations were observed (R Core
Team, 2014). IC90 determination was performed in 96-well
microtiter plates with a two-fold drug gradient that consisted
of 10 drug concentrations that were prepared in LB broth;
each well had a volume of 100 µL and was inoculated with
1 µL bacterial culture to provide each well with an initial
inoculum of 1 × 10 CFU/mL. Each plate had eight biological
replicates. The plates were incubated for 18 h at 37◦C, and
the OD600 values were read on a Synergy H1 plate reader
(BioTek Instruments Inc., Winooski, VT, United States). The
data were analyzed with Prism and IC90 values were calculated
with point-to-point curve analysis Prism 6 (GraphPad Software
Inc.).
To calculate the doubling time of each of the bacterial
strains, overnight cultures in LB medium were diluted to
1 × 106 CFU/mL and then added to 96-well microtiter plates
to which a two-fold serial dilution of antibiotics was added
with a medium negative control; all were performed with four
biological replicates. Growth of the samples was performed at
37◦C with shaking for 10 s, and kinetic measurements performed
on ELx808 absorbance microplate reader with Gen5 software
(BioTek Instruments Inc., Winooski, VT, United States). Optical
density measurements were taken at 630 nm (OD630) every
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10 min. Exponential growth was defined as OD630 values of
between 0.02 and 0.1. To calculate relative growth, R statistical
software was used to find the doubling time (Td) of each of
the strains, as well as the standard deviation (Td SD) (R Core
Team, 2014). Plots were generated with prism 6 (GraphPad
Inc.).
RESULTS
Selection of Loci for Population
Sequencing
We specifically targeted putative resistance loci that were
identified by Munck et al. (2014) through the whole-genome
sequencing of evolved isolates. As a template, we used DNA
isolated from the evolving populations that were sampled
every 48 h during the experiment. The following genomic
loci used for each drug condition based on previously end-
point sequenced mutant alleles were: cpxA, fusA, and sbmA
(AMK); marR and rob (CHL); acrR, gyrA, and soxR (CIP);
cpxA and marR (AMK + CHL); and acrR, marR, gyrA, and
soxR (CHL + CIP). These genes are implicated in either multi-
drug resistance or specific-drug resistance. The genes implicated
in multi-drug resistance include global regulators that induce
the up-regulation of acrAB-TolC multi-drug eﬄux systems, i.e.,
acrR, marR, rob, and soxR (Chubiz et al., 2012). Mutations in
these global regulators often have generalized cross-resistance
effects across multiple antibiotic classes. By contrast, the genes
implicated in specific-drug resistance are gyrA mutations (Fu
et al., 2013) that confer CIP resistance and mutations of cpxA
(Girgis et al., 2009), fusA (Johanson and Hughes, 1994), and
sbmA (Chubiz et al., 2012; Puckett et al., 2012) that confer AMK
resistance.
Allele Dynamics Differ between
Single-Drug and Drug-Combination
Evolved Populations
Our sample collection consisted of 90 samples obtained from 15
bacterial populations (triplicate lineages of five drug conditions).
Three of these drug conditions involved single drugs, i.e., AMK,
CHL, and CIP, and the remaining two drug conditions involved
the drug combinations of AMK–CIP and CHL–CIP. The
triplicate parallel lineages were assigned letters from A–C and
were sampled at six time points (days 2, 4, 6, 8, 10, and 12;
Figure 1A). We extracted genomic DNA from these samples,
amplified the loci of interest, verified the products by gel
electrophoresis, pooled the amplicons comprising targeted alleles
based on drug condition and time point, barcoded the amplicons
with indices, and pooled these together to form a sequencing
library. The library was sequenced using the MiSeq sequencing
platform to establish the frequency of mutants in each of
the selected loci (see Materials and Methods and Figure 1B).
A minimum coverage of 1000 sequencing reads per amplicon was
required before further data processing (Supplementary Figures
S1–S5).
From this data, we compared the allele dynamics of the
single-drug evolved populations with those of the combination
drug-evolved populations. It is assumed that antibiotic
combinations can suppress antibiotic resistance evolution
compared with drug monotherapy. However, we have previously
shown that this is not always the case; rather, only combinations
with collateral sensitivity interactions seem to suppress drug
evolution (Munck et al., 2014). We performed a Holm–Sidak
multiple comparison two-way ANOVA statistical test to compare
the cumulative frequency of mutations for the sequenced loci
between the different drug conditions (Figure 2). We found
spurious differences between the single- and combination-drug
conditions in cumulative frequency of mutations for specific loci.
However, two loci exhibited consecutive significant differences
over two or more time points. These were the fusA gene and the
sbmA gene in which mutations were significantly less frequent
in the AMK–CHL drug-evolved populations compared with the
AMK drug-evolved populations (P-value ≤ 0.001, Holm–Sidak
multiple comparison two-way ANOVA test; Figure 2B). Similar
results were observed in the work of Munck et al. (2014) and
likely results from collateral sensitivity to CHL caused by these
mutations (Macvanin et al., 2005; de Cristobal et al., 2008).
Populations Exhibit Complex Allele
Dynamics during Antibiotic Resistance
Evolution
To focus on important alleles within our populations, we selected
all alleles that appeared in at least one time point with a
population frequency ≥ 30% (Supplementary Figure S6). We
observed five mutations that occurred in parallel evolution events
in different adapted populations (AMK: cpxA Trp184Arg, fusA
Pro610Gln; AMK–CHL: acrR Lys55Glu; CIP and CHL–CIP: gyrA
Ser83del; CHL–CIP: soxR Arg20Cys). Of these mutations, two
have not previously been reported in the literature, namely,
acrR Lys55Glu in AMK–CHL populations and cpxA Trp184Arg
in AMK populations. We speculate that the acrR Lys55Glu
mutation confers resistance to the CHL component in the
AMK–CHL populations via the up-regulation of the acrAB-TolC
multi-drug eﬄux pump, whereas cpxA Trp184Arg confers AMK
resistance by modifying the membrane stress response.
The most prevalent mutation in the evolved bacterial
populations was gyrA Ser83del, which was observed in three
CHL-CIP and two CIP populations at several time points. The
gyrA gene often mutates at amino acid position 83; however, it has
only been reported once that the mutation was due to a deletion
of the codon (Jaktaji and Mohiti, 2010), as seen within our data.
We observed a high prevalence of this mutation, especially in the
CHL-CIP lineage A; on day 12, this mutation was observed at
a frequency of 100% in the population. However, this mutant
allele was not detected by Munck et al. (2014) possibly due to
the use of whole-genome sequencing of a representative isolate
from the population that was performed on day 14. To support
our findings, we have provided a picture of our population
result (Supplementary Figure S7) and an additional Sanger
sequencing result of the population to re-confirm our findings
(Supplementary Figure S8).
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FIGURE 2 | Comparison of the cumulative mutational frequencies of the gene loci for each drug condition over the deep-sequencing time points
(A) The cumulative mutation frequencies calculated for each time point after the removal of all mutations below 5%; from left to right, AMK (showing the cpxA, fusA,
and sbmA gene loci), CHL (showing the acrR, marR, rob, and soxR gene loci) and AMK-CHL (showing the acrR, cpxA, fusA, marR, rob, sbmA, and soxR gene loci),
from left to right, CHL (showing the acrR, marR, rob, and soxR gene loci), CIP (showing the acrR, gyrA, rob, and soxR gene loci) and CHL-CIP (showing the acrR,
gyrA, marR, rob, and soxR gene loci). (B) Heat-map illustrating the differences in the cumulative mutational frequencies of the gene loci of interest and the drug
combinations compared with the single-drug counterparts at each time point based on a Holm-Sidak multiple comparison two-way ANOVA (all of the dark gray
points are not significant, and all of the blue points are significant with P-values below 0.0001).
Within our data, we observed three distinct allele dynamics
(Figure 3A), which we termed as follows: interfering allele
dynamics in which the mutant alleles have opposing dynamic
trajectories (Figure 3A); super-imposing allele dynamics in
which the mutant alleles have the same frequency trajectories
(Figure 3B); and fixation allele dynamics in which one allele fixes
in the population and provides the genetic background in which
new alleles appear (Figure 3C).
We observed interfering allele dynamics in the following
three populations: CIP lineage B, AMK lineage B, and CHL
Lineage C. We assume that clonal interference is the most
likely cause of our observations, but in some cases, it
could be due to mutational incompatibility. For instance,
we were able to demonstrate direct antagonistic interactions
between the two mutations in the CIP lineage B because
both mutations were captured within a single read. We
observed that the individual reads from this lineage either
had an amino acid change in gyrA at position Ser83del
or Asp87Gly for the time points from 4 to 12. However,
further experimentation is required to deduce which effect
is responsible for our other observations of interfering allele
dynamics.
We observed super-imposing allelic dynamics in the following
three populations: AMK lineage C, CHL–CIP lineage A, and
CIP lineage A. For all three populations, the two mutant alleles
exhibited similar population frequencies over multiple time
points (Figure 3C). Such fixation patterns likely result from
the quick succession of two separate mutations within a cell.
Because our population sequencing was performed only every
48 h, we likely were unable to resolve the successive occurrence
of these mutations. These observations could be the result of
two possible effects. The first is the hitchhiking effect in which
a neutral mutant allele co-occurs with a beneficial mutant allele
and, due to the selective advantage provided by the beneficial
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FIGURE 3 | Epistatic mutation interaction observation of the whole bacterial population. Epistatic mutation interaction observation of the whole bacterial
population with the three types of mutational interactions shown with three examples each of (A) all interfering allelic dynamics; the mutational areas form different
fractions of the population shown in either red fill or gray fill, from left to right CIP-Lineage B (with gyrA Asp87Gly in gray line and fill and gyrA Ser83del in red line),
AMK-Lineage B (with sbmA Ala169Glu in gray line and cpxA Trp184Arg in red line) and CHL-Lineage C (with rob Arg156His in gray and marR Gln110∗ in red line).
(B) Super-imposing allelic dynamics in which both mutations are present at the same time. The mutational frequency area is in purple fill; in this situation, it is
assumed that both mutations are co-existing in the bacterial cells, from left to right, AMK-Lineage C (with cpxA Ala79Val in gray line and fusA Ala608Val in red line),
CHL–CIP Linage A (with gyrA Ser83del in gray line and marR Val84Glu in red line) and CIP Lineage A (with gyrA Ser83del in gray line and soxR
Ser126_Arg127delinsSer in red line). (C) Population fixation allele dynamics in which the mutations that increase the frequency area are shown in gray fill. The
second mutation arises in the background of the first; therefore, we assume that both are present within the bacterial cells; for this situation, purple frequency area fill
was used, from left to right AMK-Lineage B (with fusA Pro610Gln in gray line and cpxA Asp31Tyr in red line), CHL-Lineage B (with marR Arg86Trp in gray line and
rob Arg156His in red line) and CIP-Lineage A (with gyrA Asp87Tyr in gray line and gyrA Gly75Ser in red line).
allele, the neutral mutation is therefore irreversible (Taddei et al.,
1997; Tenaillon et al., 1999). The second is that both mutations
contribute to the selected phenotype (Blount et al., 2008; Fogle
et al., 2008; Wong and Seguin, 2015). We are not able to make
a distinction between these two scenarios based on our allele
frequency data alone.
For the fixation allele dynamics, we observed one allele that
fixes at 100% in the population followed by the establishment of
a subsequent allele. This pattern was observed in the following
three populations: AMK lineage B, CHL lineage B, and CIP
Lineage A.
In summary, we observed interfering allele dynamics in five
populations, superimposing allele dynamics in seven populations
interactions and fixation allele dynamics in eight populations
(Table 2). This highlights that diverse population dynamic
patterns can be observed during laboratory antibiotic resistance
evolution.
Recombineering Permits the Validation
of Interactions between Genotypes
To follow up on our observations, we used recombineering to
engineer strains with our observed mutant alleles. This process
was performed with a subset of detected mutations that exhibited
superimposing establishment or interfering allele dynamics. By
measuring the relative growth rates and antibiotic tolerance of
the isogenic mutants compared with those of the ancestral wild
type, we were able to deduce the basis of some allele dynamics
(Figure 4).
In the CHL lineage C population, we observed interfering
allele dynamics. In particular, we observed that the rob G467A
allele became dominant in the population and that the marR
C328T was lost from the population from day 6 onward
(Figure 3A). Therefore, we constructed three bacterial strains:
MG1655: rob G467A, MG1655: marR C328T, and MG1655:
marR C328T+rob G467A, and tested the relative growth rate
and CHL IC90 for each strain relative to the wild type
(Figure 4A). We find that the rob G467A strain was selected
due to its increased antibiotic resistance compared with the
marR C328T strain (Figure 4A). The rob G467A strain exhibited
a 6-fold increase in the IC90 relative to the ancestral wild
type, whereas the marR C328T strain exhibited a 5.5-fold
increase. Even though this difference in IC90 values is small
it suggests that the observed fixation patterns in the CHL
lineage C population resulted from clonal interference and
not mutational incompatibility. To validate this assumption,
we constructed the double mutant marR C328T+rob G467A;
this strain was viable and exhibited CHL IC90 11-fold higher
than the ancestral wild type. The double mutant did exhibit
a reduced growth rate in absence of antibiotics compared to
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TABLE 2 | Observed allelic dynamics.
Dynamics Drug condition Lineage Mutation(s)
Interfering (5) AMK A cpxA Asp31Tyr + fusA Pro610Gln/fusA Pro610Thr
AMK B cpxA Trp184Arg/sbmA Ala169Glu
AMK C cpxA Ala79Val + fusA Ala608Gln/fusA Thr674Ala
CHL C marR Gln110∗/rob Arg156His
CIP B gyrA Asp87Gly/gyrA Ser83del
Super-imposing (7) AMK A cpxA Asp31Tyr + fusA Pro610Gln
AMK B cpxA Trp184Arg + fusA Ala608Gln
AMK C cpxA Ala79Val + fusA Ala608Val
CHL B acrR Ala156Ser + rob Arg156His
CIP A gyrA Asp87Tyr + soxR Ser126_127delinsSer
AMK–CHL B acrR Gln183Lys + acrR Met175Arg
CHL–CIP A gyrA Ser83del + marR Val84Glu
Population Fixation (8) AMK A fusA Pro610Thr
AMK A sbmA Asp194Asn
AMK B cpxA Trp184Arg + fusA Pro610Gln
AMK C cpxA Trp184Arg
CIP A gyrA Asp87Tyr + soxR Ser126_Arg127delinsSer
CIP C acrR Ser25∗
CIP C gyrA Gly81Cys
CIP C soxR Arg127_Ser128delinsArg
∗Non-sense mutation.
FIGURE 4 | Evaluation of the strains based on the relative growth rates and IC90 fold changes relative to the ancestral wild-type (green on the plots
represents a relative growth rate ≥ 1 and a IC90 fold change from the wild type above ≥ 10, and red represents a relative growth rate ≤ 0.5 and a
IC90 fold change from wild type above ≤ 2), and the doubling times at varying antibiotic concentrations (A). Strains were recombineered to assess the
clonal interference mutation interactions between genotypes based on mutations found in the CHL-Lineage C (the strains are labeled accordingly on the right-hand
side). Strains were recombineered to access the super-imposing establishment mutation interactions between genotypes based on the mutation found in the
CHL–CIP Linage A (the strains are labeled accordingly on the right-hand-side) (B). The doubling times at various chloramphenicol concentrations were plotted for all
recombineered strains and the ancestral wild type based on the mutation found in CHL-Lineage C (the strains are labeled accordingly on the right-hand side). The
doubling times at various chloramphenicol + ciprofloxacin concentrations were plotted for all recombineered strains and the ancestral wild type based on the
mutation found in the CHL–CIP Linage A (the strains are labeled accordingly on the right-hand side).
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the single mutants and the ancestral wild type. However, when
quantifying the growth rate of the strains in the presence
of different CHL concentrations we observed that the double
mutant was able to sustain growth up to concentrations
of 8 mg/L CHL (doubling time of 54 min), whereas both
single-mutant allele strains could only sustain growth in CHL
concentrations up to 2 mg/L (the doubling time for marR
C328T and rob G467A was 40 and 60 min, respectively).
Finally, the ancestral wild type could sustain growth in CHL
concentrations up to 2 mg/L with a doubling time of 57 min
(Figure 4B). Accordingly, the double mutant could have been
selected for in the experiment at CHL concentrations above
2 mg/L.
For our super-imposing allele dynamics, we tested our
observations in the CHL–CIP lineage A population in which
gyrA 247_249delTCG and marR T251A appeared at the same
frequency from day 8 (Figure 3B). These observed mutations
likely complement each other since gyrA 247_249delTCG would
confers target mediated resistance against CIP (Fu et al., 2013),
and marR T251A induces up-regulation of the acrAB-TolC
multi-drug eﬄux pump that causes collateral resistance to
both CHL and CIP (Chubiz et al., 2012). Therefore, we
recombineered three bacterial strains, i.e., MG1655: gyrA
247_249delTCG, MG1655: marR T251A, and MG1655: gyrA
247_249delTCG + marR T251A, and quantified the doubling
time and CHL–CIP tolerance relative to the ancestral wild type
(Figure 4A). We found that the double mutant exhibited strong
selective advantage compared to the single mutants and the
ancestral wild type in the presence of CHL–CIP. The IC90
of the double mutant was 11-fold higher than that of the
ancestral wild type, and the corresponding values were 4.3-fold
and 6.6-fold for the single mutants gyrA 247_249delTCG and
marR T251A, respectively. The doubling time of the double
mutant was 59% higher than the ancestral wild type when
grown without antibiotic. Yet, in the presence of CHL–CIP the
double mutant had a substantially lower doubling time than
the single mutants and the ancestral wild type (Figure 4). The
double mutant was able to sustain growth at concentrations of
CHL–CIP up to 8.0116 mg/L (doubling time of 98 min). Both
of the single-mutants could sustain growth at concentrations of
CHL–CIP up to 2.004 mg/L (doubling time for marR T251A and
gyrA 247_249del TCG was 58 and 124 min, respectively). The
ancestral wild type sustained growth at CHL–CIP concentrations
up to 2.004 mg/L (doubling time of 89 min). Based on these data
it is obvious that if a double mutant was present in a population
containing both single-mutants and wild type cells it would
rapidly outcompete these other strains as antibiotic exposure
increased.
DISCUSSION
There are many studies that report the genomic evolutionary
trade-offs that occur during adaptive evolution and are
supported by end-point whole-genome sequencing of single
or multiple isolates (Lázár et al., 2013; Kim et al., 2014;
Munck et al., 2014; Oz et al., 2014). Understanding these
genomic trade-offs is essential for application of antibiotic
collateral sensitivity treatments of drug cycling (where genomic
evolution to one drug causes hyper-sensitivity to another
drug) or combination treatments (where genomic evolution is
constrained due to lack of genomic cross-resistance). These
studies provide important genomic information but do not
quantify the frequency of a given mutations in the whole
population at the end of adaption or during adaptation. In this
study, we present a method of time-resolved tracking of known
genomic loci to evaluate the dynamics of putative resistance
alleles.
We demonstrate the importance of tracking known genomic
loci involved in antibiotic resistance to our drugs AMK,
CHL, CIP, AMK–CHL, and CHL–CIP on a population level.
We observe the reduced frequency of mutant alleles for fusA and
sbmA in the AMK–CHL adapted populations compared to the
AMK adapted populations. This is likely a result of the collateral
sensitivity conferred by these mutant alleles toward CHL (Munck
et al., 2014). However, we did observe cpxAmutant alleles develop
in populations during adaptation toward AMK–CHL although
at a reduced population frequency compared to AMK evolved
populations.
We observed diverse allele dynamics in the adapting
populations. These can be grouped into three categories:
superimposing allele dynamics (Fogle et al., 2008); interfering
allele dynamics (Gerrish and Lenski, 1998; de Visser and Rozen,
2006; Jerison and Desai, 2015); and fixation allele dynamics
(Wilke, 2004; de Visser and Rozen, 2006; Good et al., 2012). All
dynamic patterns where observed in this experiment highlighting
the diversity of the evolutionary trajectories selected for during
antibiotic resistance evolution.
Due to accessibility and reduced costs of next-generation
sequencing, re-sequencing tools, such as amplicon population
sequencing, are gaining popularity in the publication of other
adaptive evolution studies (Ostman et al., 2012; Wong and
Seguin, 2015; Feng et al., 2016) and the analyses of clinical and
environmental samples (Johnning et al., 2015; Fischer et al.,
2016; Greipel et al., 2016). While this method is powerful,
it is limited in a number of ways. First, it requires a priori
knowledge and selection of the loci to investigate. This selection
likely leads to missing important mutants that occur outside
the selected loci. Second, it is challenging to capture genomic
duplication events such as occurs in adaptive evolution by the
gene innovation–amplification–divergence model (Näsvall et al.,
2012). Using our amplicon sequencing, we would assume that
the diverged duplicated gene would confer resistance in our gene
loci of interest, and in this instance, this assumption would be
incorrect.
Nonetheless, we believe that these population wide loci
specific approaches will play a critical role in in vitro
adaptation evolution experiments and, with methodological
modification, could extend to in vivo population sequencing
studies. For example, with our sequencing method, we observed
cross-resistance in bacterial clones within the CHL–CIP Lineage
A population that was due to mutations in gyrA and marR,
and a similar resistance mechanism has been described for
fluoroquinolone resistance (Marcusson et al., 2009). To further
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evaluate this issue, we reconstructed an isogenic strain containing
our gyrA and marR mutant, and we observed that this isogenic
mutant strain was able to persist at four-fold greater CHL
and CIP concentrations compared with its ancestral wild type.
Although this strain did exhibit a fitness cost, if the double-
mutant isogenic strain and the ancestral wild type were in
an environment with a concentration of CHL + CIP above
1.002 mg/L, the double-mutant isogenic strain would outcompete
the ancestral wild type. If this mutant was also able to
undergo further evolution and develop fitness compensation
mutations to restore fitness, then this strain would persist in
environments with or without CHL and CIP (Andersson and
Hughes, 2010).
These methodologies will be important in several situations,
including the monitoring of chronic conditions that require
long-term antibiotic treatment, i.e., chronic urinary tract
infections (Blango et al., 2014; Nolan et al., 2015) and
cystic fibrosis patients colonized with Pseudomonas aeruginosa
(Folkesson et al., 2012) and Staphylococcus aureus infections
(Vanderhelst et al., 2012).
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FIGURE S2 | Coverage plots for each investigatory amplicon for the CHL
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FIGURE S3 | Coverage plots for each investigatory amplicon for the CIP
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FIGURE S4 | Coverage plots for each investigatory amplicon for the
AMK–CHL drug condition.
FIGURE S5 | Coverage plots for each investigatory amplicon for the
CHL–CIP drug condition.
FIGURE S6 | Significant variant tracking for each drug condition in which
the mutations that appear at 30% or more at any given time point are
plotted. Mutations listed in black appear in all three lineages, those in dark gray
appear in two lineages, and those in light gray appear only in one lineage. From
left to right, AMK Lineage A [featuring the cpxA (dark green fill): Asp31Tyr (circle),
Trp184Arg (square), fusA (mid-dark green fill): Pro610Gln (up-triangle), Pro610Thr
(down-triangle); and sbmA (lightest green fill): asp194Asn (hexagon with dot)
mutation], AMK Lineage B illustration of mutations cpxA (dark green fill): Asp31Tyr
(circle), Trp184Arg (square); and fusA (mid-dark green fill): Pro610Gln (up-triangle),
sbmA (lightest green fill): Asp194Glu (circle with dot). AMK Lineage C illustration of
the cpxA (dark green fill): Asp31Tyr (diamond with dot), Trp184Arg (square); fusA
(mid-dark green fill): Ala608Val, Pro610Gln (up-triangle), Pro610Thr
(down-triangle), Thr647Ala (square with diagonal cross); sbmA (lightest green fill):
Trp250∗ (diamond with cross). From left to right, CHL Lineage A [featuring the
mutation rob (mid-dark purple): Gly245Arg (star)], CHL Lineage B [featuring the
mutations acrR (light purple): Ala156Ser (circle with diagonal cross); marR
(mid-light purple): Arg86Trp (square); and rob (mid-dark purple): Arg156His circle].
CHL Lineage C illustration of the mutations acrR (light purple): Arg209fs (hexagon);
marR (mid-light purple): Arg86Trp (square), Gln110∗ (down-triangle); and rob
(mid-dark purple): Arg156His (circle). From left to right, CIP Lineage A [featuring
the mutations gyrA (mid-light green): asp87Tyr (circle), Gly75Ser (up-triangle),
ser83del (square); soxR (dark purple): Ser126_Arg127delinSer (diamond with
cross)]. CIP Lineage B illustration of the mutations gyrA (mid-light green): asp87Gly
(diamond), ser83del (square); rob (mid-dark purple): and Arg156His (hexagon with
diagonal cross). CIP Lineage C illustration of the mutations acrR (light purple):
Ser25∗ (hexagon); gyrA (mid-light green): Gly81Cys (circle with diagonal cross),
soxR (dark purple): Arg127_Ser128delinsArg (down-triangle). From left to right,
AMK–CHL Lineage A [featuring the mutations acrR (light purple): Lys55Glu (circle);
cpxA (dark green): Ala187Thr (square), Ile382_Thr383delinMetLeu (up-triangle),
Ser175Cys (down-triangle); and soxR (dark purple): Ala18Glu (hexagon), glu150fs
(square with diagonal cross)]. AMK–CHL Lineage B [featuring mutations; acrR
(light purple): Asp157Asn (star), Cys205Phe (square), Lys55Glu circle and
Met175Arg] and AMK–CHL Lineage C [featuring acrR (light purple): Ala156Ser
(diamond) with Ala156Ser, Arg209fs (square with diagonal cross), Lys55Glu; cpxA
(dark green): Ala187Thr and soxR (dark purple) Ala18Glu hexagon]. From left to
right, CHL–CIP Lineage A [featuring the mutations gyrA (mid-light green): Phe96fs
(circle), Ser83del (square); marR (mid-light purple): Cys51Ser (half-dark
up-triangle), Val84Glu (down triangle); soxR (dark purple): Arg20Cys square]
CHL–CIP Lineage B [the mutations acrR (light purple): Cys205delinsCysArg
(circle), Thr5Ala (half dark circle); gyrA (mid-light green): Ser83del (square); soxR
(dark purple): Arg20Cys (square), Ser126_Arg127delinsCys (diamond)] and
CHL–CIP Lineage C [the mutations acrR (light purple): Cys205delinsCysArg
(circle); gyrA (mid-light green): Ser83del (square); soxR (dark purple): Arg20Cys
(square), Ser126_Arg127delinsSer (up-triangle)].
FIGURE S7 | Population verification of CHL-CIP Lineage A Day 12.
FIGURE S8 | Sanger sequence verification of CHL-CIP Lineage A Day 12.
TABLE S1 | Primers used for the generation of the amplicons.
TABLE S2 | Variant detection table.
TABLE S3 | Homologous recombineering oligos and verification primers.
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